Literature DB >> 24659543

The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia.

Hector Ortega1, Geoffrey Chupp2, Philip Bardin3, Arnaud Bourdin4, Gilles Garcia5, Benjamin Hartley6, Steve Yancey7, Marc Humbert8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24659543     DOI： 10.1183/09031936.00220413

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  21 in total

1.  Obese asthmatic patients have decreased surfactant protein A levels: Mechanisms and implications.

Authors:  Njira Lugogo; Dave Francisco; Kenneth J Addison; Akarsh Manne; William Pederson; Jennifer L Ingram; Cynthia L Green; Benjamin T Suratt; James J Lee; Mary E Sunday; Monica Kraft; Julie G Ledford
Journal:  J Allergy Clin Immunol       Date:  2017-06-15       Impact factor: 10.793

Review 2.  Severe Asthma in Children.

Authors:  Bradley E Chipps; Neil G Parikh; Sheena K Maharaj
Journal:  Curr Allergy Asthma Rep       Date:  2017-04       Impact factor: 4.806

Review 3.  Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential.

Authors:  Francesco Menzella; Mirco Lusuardi; Carla Galeone; Sofia Taddei; Nicola Facciolongo; Luigi Zucchi
Journal:  Ther Adv Chronic Dis       Date:  2016-08-11       Impact factor: 5.091

Review 4.  Anti-IL-5 therapies for asthma.

Authors:  Hugo A Farne; Amanda Wilson; Stephen Milan; Emma Banchoff; Freda Yang; Colin Ve Powell
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

5.  Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

Authors:  Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

6.  TH17 cells and corticosteroid insensitivity in severe asthma.

Authors:  Yan Xie; Peter W Abel; Thomas B Casale; Yaping Tu
Journal:  J Allergy Clin Immunol       Date:  2021-12-23       Impact factor: 10.793

Review 7.  Anti-IL5 therapies for asthma.

Authors:  Hugo A Farne; Amanda Wilson; Colin Powell; Lynne Bax; Stephen J Milan
Journal:  Cochrane Database Syst Rev       Date:  2017-09-21

8.  Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma: A retrospective analysis.

Authors:  Richard P Ramonell; F Eun-Hyung Lee; Joshua M Levy; Merin Kuruvilla
Journal:  Ann Allergy Asthma Immunol       Date:  2020-09-10       Impact factor: 6.248

Review 9.  Anti-IL5 therapy for asthma and beyond.

Authors:  Manali Mukherjee; Roma Sehmi; Parameswaran Nair
Journal:  World Allergy Organ J       Date:  2014-12-04       Impact factor: 4.084

Review 10.  Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.

Authors:  Francesco Menzella; Mirco Lusuardi; Carla Galeone; Sofia Taddei; Luigi Zucchi
Journal:  J Asthma Allergy       Date:  2015-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.